Cancer Biomarkers

What Are Biomarkers and Precision Medicine in Oncology? An Interview with W. Michael Korn, MD
Cancer Biomarkers
Precision medicine in cancer is an approach to medicine that uses tailored treatment for the individual patient based on the specific disease characteristics that are unique for each patient. This approach recognizes that each patient is medically different, and that the way the disease is manifested in the patient is also different.
Genetic, Genomic, or Biomarker Testing in Cancer—What Is the Difference?
Cancer BiomarkersGenetics & Cancer
Genetic testing. Genomic testing. Molecular profiling. Biomarker testing. Germline testing. Inherited mutation testing. Somatic tumor testing. Pathogenic variant. Variant of uncertain significance. Do patients need to know any of these terms, and do they all mean the same thing or different things? How can patients make sense of all these terms and be sure they get the right test to ensure they receive the best available treatment?
What on Earth Is a “Biomarker”?
Ovarian CancerCancer BiomarkersCancer ScreeningIssue Introductions
In her Introduction to the special edition of CONQUER titled Understanding Biomarkers & Molecular Testing, Lillie D. Shockney, RN, BS, MAS, ONN-CG, briefly explains what biomarkers are, why they are important, and what you should know about them.  
Understanding Hereditary Biomarkers Versus Tumor-Specific Biomarkers—What’s the Difference?
Cancer BiomarkersGenetics & CancerPersonalized Medicine
One-size-fits-all medicine is a thing of the past. Cancer, at its core, is a genetic disease. Today’s advances in cancer research mean that doctors can now tailor a personalized treatment to the patient’s specific cancer type.
My Biomarker Story, and Why I Advocate for Genetic Testing
Cancer BiomarkersPatient AdvocacyPatient Stories
Wenora Y. Johnson, 3-time survivor, shares her cancer story and encourages patients to ask their care team about biomarker testing.
Blincyto First Drug Approved for ALL and the MRD Biomarker
Cancer BiomarkersFDA Approvals, News & UpdatesLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
What Are Biomarkers in Breast Cancer, and How Do They Affect My Treatment? Interview with Daniel F. Hayes, MD, FACP, FASCO
Breast CancerCancer BiomarkersCancer Screening
Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer.
New Developments in Cancer Biomarkers Reported at AACR 2018
Cancer Biomarkers
Read about important advancements in tumor biomarkers and their role in guiding treatment in some types of cancer.
Growing Role of Biomarkers in the Treatment of Patients with Acute Myeloid Leukemia
Cancer BiomarkersLeukemia
In recent years, new treatments for acute myeloid leukemia have improved outcomes. In 2017, 2 new drugs were approved for patients with this type of blood cancer linked to a specific biomarker.
Page 1 of 2
Results 1 - 10 of 14

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.